top of page
Writer's pictureNoel Ong

LTR Pharma soars with ground breaking erectile dysfunction nasal spray

Since its December listing, LTR Pharma (ASX: LTP) has made impressive strides, with its share price rising 60% following the launch of its innovative SPONTAN nasal spray for erectile dysfunction (ED).

LTR Pharma (ASX: LTP) has made impressive strides with the launch of its innovative SPONTAN nasal spray for erectile dysfunction (ED).| Samso Insights on Patreon | Samso

This first-of-its-kind treatment promises to deliver results in 10 minutes or less, disrupting the global PDE5 market dominated by oral medications like Viagra. LTR is currently conducting a pivotal clinical study, comparing SPONTAN's efficacy to oral Vardenafil, with data expected by mid-2024.

This blog is ideal for investors interested in cutting-edge biopharmaceutical innovations with the potential to revolutionise a multi-billion-dollar market. LTR Pharma’s progress offers a compelling opportunity for those looking to invest in breakthrough healthcare solutions.


Ready to Do Your Own Research? Sign up for your membership on Samso Insights on Patreon now for support in boosting your investment research.



 

Three types of membership on Samso Insights


Choose one or more:

  1. FREE: These insights are free and available to all investors. Subscribe here for free.

  2. PAID MEMBERSHIP: If you are a bold investor and want more, you get access to the latest and most reliable information from experienced sources that are completely unbiased starting from US$10/month. Start accessing our exclusive content to help with your investment research.

  3. PAID ARTICLES: Trustworthy source of well-researched and independent information for investors. Choose what interests you and unlock your choice of article from US$10.







 

Disclaimer

The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints. Read full Disclaimer.


If you find this article informative and useful, please help me share the information.  I try and write about topics that are interesting and have the potential to be of investment value.  It is not easy to find stories that fit those parameters. If you or your organisation see the benefit of what Samso is trying to achieve and have a need to share your journey, please contact me on noel.ong@samso.com.au.


 


Comments


bottom of page